Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|December 1, 2008
Moheb M. Nasr, PhD
Moheb M. Nasr, PhD is a Pharmtech editorial advisory board (EAB) member.
Advertisement
Moheb M. Nasr, PhD
Director,
Office of New Drug Quality
Assessment, CDER/FDA
Moheb Nasr is the director of the Office of New Drug Quality Assessment (ONDQA), in the Center for Drug Evaluation and Research (CDER), at the US Food and Drug Administration. ONDQA is responsible for quality assessments (pre- and postmarketing) of new drugs regulated by CDER. Nasr obtained his PhD degree in Chemistry at the University of Minnesota in Minneapolis.
Nasr holds a BS degree in Pharmacy and a Master’s degree in Pharmaceutical Analysis, both from Cairo University, Egypt. Nasr joined FDA in 1990, and assumed his current position in June 2003. He is leading the restructuring of the pharmaceutical quality assessment program at FDA. Nasr is a member of FDA’s Council on Pharmaceutical Quality, and is an elected fellow of the American Association of Pharmaceutical Scientists (AAPS).
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement